FODMAPFABRYNCT07888998
Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients
StatusActive, Not Recruiting
PhaseNot applicable
SponsorAcibadem University
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Eligibility criteria expanded, about 7 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Change in Gastrointestinal Symptom Rating Scale (GSRS) Score
Timeframe: Baseline and Week 6
Change in Plasma Neopterin Levels
Timeframe: Baseline and Week 6
Change in Interleukin-6 (IL-6) Levels
Timeframe: Baseline and Week 6
Change in Tumor Necrosis Factor-alpha (TNF-α) Levels
Timeframe: Baseline and Week 6
Change in Plasma Biopterin Levels
Timeframe: Baseline and Week 6
Secondary (3)
Change in Short Form-36 (SF-36) Health Survey Scores
Change in Bristol Stool Form Scale Classification
Change in Lyso-Globotriaosylceramide (Lyso-Gb3) Levels
Arms and interventions
Low-FODMAP Diet GroupExperimental
Participants will receive an individualized low-FODMAP diet for six weeks, with daily online monitoring of dietary adherence.
Control GroupNo intervention
Participants will continue their habitual unrestricted diet for six weeks without receiving a specific dietary intervention.
Behavioral: Low-FODMAP Diet
Sites
1 site in 1 country
- Istanbul University-Cerrahpasa, Cerrahpasa Faculty of MedicineIstanbul, Fatih, Turkey (Türkiye)